- Motley Fool
Can Ocugen Stock Keep Churning Higher?
This tiny biotech caught fire in 2024. Can it sustain the momentum?
- Zacks
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Ocugen (OCGN) is expected to provide updates regarding the developmental program of its lead candidate, OCU400, for two rare retinal diseases in the first-quarter earnings release.
- Zacks
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
Ocugen (OCGN) stock gains as the DSMB for the phase I/II study of OCU410 approves the initiation of dosing with the medium dose of OCU410 in the dose-escalation phase of the GA study.
